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Abstract: Hypertension is common in Asian populations and is a major cause of cardiovascular 
diseases. The prevalence of hypertension is increasing in many Asian countries. The overall preva-
lence of hypertension in India and the People’s Republic of China has been estimated to be 20.6% 
in men and 22.6% in women. However, the rates of detection, treatment, and control of hyperten-
sion remain low in Asia. This reflects a low level of literacy and education, as well as a low level of 
access to medical care. To overcome these obstacles, strategies targeted at education, promotion, 
and optimization of medical care, are crucial to achieve target blood pressure control. Angiotensin 
receptor blockers are one of the first-line treatments for essential hypertension because they con-
fer better cardiovascular outcomes. Losartan has been widely evaluated for the management of 
hypertension. Although some studies suggested that the blood pressure-lowering effect of losartan 
is perhaps lower than for other angiotensin receptor blockers, losartan has been demonstrated to be 
beneficial in terms of renal protection in patients with diabetes, heart failure resulting from either 
systolic or diastolic dysfunction, and diuretic-induced hyperuricemia. However, most of these data 
were obtained from Caucasian populations. The efficacy and safety of losartan in Asian popula-
tions may be different because of genetic and ethnic variations. Therefore, the efficacy and safety 
of losartan in Asian patients with hypertension warrant further study.
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Introduction
Hypertension is common in Asian populations and is a major cause of cardiovascular 
diseases. The prevalence of hypertension is increasing in many countries. Nowadays, 
a quarter of the world’s adult population has hypertension, and this percentage is likely 
to increase to 29% by 2025.1
Lifestyle modification is important for patients with hypertension. Previous studies 
have shown that smoking, heavy alcohol consumption, a diet high in salt, and a sed-
entary lifestyle are associated with hypertension. However, lifestyle modification 
alone is usually not sufficient to control high blood pressure. Most of the patients 
require antihypertensive medications to achieve the target blood pressure, and among 
those who require drug treatment, more than 70% of the patients require the use of 
two or more antihypertensive drugs.2
The British guidelines on the management of hypertension were updated in August 
2011. In the new guidelines, patients younger than 55 years are recommended to receive 
an angiotensin-converting enzyme (ACE) inhibitor or a “low-cost” angiotensin recep-
tor blocker as the first-line treatment.3 Blockers of the renin-angiotensin-aldosterone 
system (RAAS) have surpassed diuretics and beta-blockers because those agents 
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were better in terms of cardiovascular outcome. Moreover, 
angiotensin receptor blockers (ARBs) and ACE were associ-
ated with a decrease in new-onset diabetes.4
Losartan has been widely evaluated for the treatment of 
hypertension. Although some studies have suggested that the 
blood pressure-lowering effect of losartan is perhaps lower than 
for other ARBs, losartan was demonstrated to be beneficial 
in terms of renal protection in patients with diabetes, heart 
failure resulting from either systolic or diastolic dysfunction, 
and diuretic-induced hyperuricemia. However, most of these 
data were obtained from Caucasian populations. The efficacy 
and safety of losartan in Asian populations may be different 
because of genetic and ethnic variations. Therefore, the efficacy 
and safety of losartan in Asian patients with hypertension are 
reviewed in this article.
Prevalence of hypertension in Asia
Hypertension is one of the major health burdens in the world. 
The prevalence of hypertension in developed countries is 
around 40%, whereas its prevalence in developing countries 
was estimated to be 25%.1 However, because of the larger 
population in developing countries, the absolute numbers of 
patients affected by hypertension are considerably higher, and 
the prevalence is likely to rise as a result of urbanization and 
improved life expectancy.
The prevalence of hypertension in India and the People’s 
Republic of China has been analyzed. The overall Indian and 
Chinese population prevalence for hypertension was 20.6% in 
men and 22.6% in women.1 The prevalence of hypertension 
in the People’s Republic of China has increased significantly 
in the last few years. In 1998, 24% of the population in the 
People’s Republic of China aged 35 to 59 years had hyperten-
sion, which was 2.3% higher than that observed from 1992 to 
1994.5 In a recent analysis of the Indian cohorts, the prevalence 
of hypertension and prehypertension was 42.5% and 41.5%, 
respectively. A national survey in Pakistan also showed that 
nowadays, 20.7% of the adult population has hypertension.6
Challenges in managing 
hypertension in Asia
In Asia, central or abdominal obesity is an important cause of 
hypertension and diabetes.7 In the Hong Kong Cardiovascular 
Risk Factor Prevalence Study, 58% of people with diabetes had 
raised blood pressure, whereas 56% of people with hypertension 
had dysglycemia.8 Several reports have suggested that Chinese 
people and South Asians had a higher prevalence of dyslipidemia, 
diabetes, and hypertension at a much lower body mass index 
than Europeans. Therefore, the International Diabetes Federation 
consensus group provided a new definition of obesity for Asians 
with a cutoff much lower for the Chinese, Japanese, and South 
Asian populations compared with that for Europeans.9
As obesity is a major cause of hypertension, and as its 
prevalence is increasing in Asia, treatment targeting obesity 
will help lower the incidence of hypertension in the future. 
People in the community must embrace a healthy lifestyle 
and change their diet and leisure activities to prevent the 
development of obesity. Asian households tend to be larger, 
and it is common for the extended family to live together. 
This means that lifestyle changes should be targeted at the 
household, rather than the individual hypertensive patient. A 
family approach should work well in Asia.
Apart from lifestyle modifications to prevent obesity, 
much effort has gone into promoting the awareness of 
hypertension. However, the rates of detection, treatment, 
and control remain low in Asia. This reflected a low level of 
literacy and education but also reflected a low level of access 
to medical care. In South Asian countries, low awareness cor-
related with poor access to treatment.10 The challenge posed 
by low levels of awareness must be overcome through strat-
egies targeted at education and promotion. Blood pressure 
measurement should be advocated in every adult. Because 
of the large population in Asian countries, ambulatory blood 
pressure is not a feasible option for detection and monitoring 
of blood  pressure. Instead, home blood pressure monitoring 
has proved to be very useful and is increasingly affordable.
Regarding drug treatment for hypertension, Asians appear 
to respond better to calcium channel blockers (CCBs) but 
have a higher incidence of dry cough with ACE inhibitors.11 
ARBs may therefore be more suitable for Asian patients.
Treatment recommendation  
for hypertension
The British guidelines on the management of hypertension, 
developed by the National Institute for Clinical Excellence, 
were updated August 2011.3 They are highly evidence-based 
and incorporate cost-effectiveness considerations. Compared 
with many other consensus guidelines, the British guidelines 
are less dependent on expert opinion but include a diverse 
range of opinions, including nonspecialists, nonclinicians, 
and the pharmaceutical industry.
In the new guidelines, there were changes to the recom-
mended first-line treatment. As before, patients younger than 
55 years are recommended to receive an ACE inhibitor or a 
“low-cost” ARB as the first-line treatment.
CCB and RAAS blockers have surpassed diuretics and 
beta-blockers as first-line drugs largely as a result of the 
Clinical Interventions in Aging 2014:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
445
Blood pressure control in Asian patients
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), 
which showed that those newer agents were better than 
the older agents in terms of cardiovascular outcome.12 
Moreover, in ASCOT and in meta-analysis, ARB and ACEI 
were associated with a decrease in new-onset diabetes, 
whereas diuretics and beta-blockers were associated with 
an increase in risk.
Clinical efficacy of losartan  
in Caucasian populations
Blood pressure control
The ARBs have an effect similar to other antihypertensive 
monotherapies. However, several studies have shown that 
losartan is less effective for controlling blood pressure when 
compared with other ARBs such as irbesartan, telmisartan, 
and valsartan.
Patients receiving 8-week treatment with 300 mg irbe-
sartan had greater reductions in systolic and diastolic blood 
pressure than those receiving 100 mg losartan, although the 
antihypertensive effect of 150 mg irbesartan did not differ 
significantly from that of 100 mg losartan.13
In a randomized controlled trial comparing the efficacy 
of telmisartan and losartan, the reductions in ambulatory 
systolic and diastolic blood pressure with telmisartan 40 mg 
and 80 mg were both significantly greater than those observed 
for losartan 50 mg. Losartan was even shown to be no better 
than placebo in this study.14
Another, similar, randomized controlled trial was pub-
lished in 1999, comparing the efficacy of valsartan and losar-
tan in patients with uncomplicated essential hypertension. 
After 4 weeks of active treatment, the medication doses were 
doubled. Valsartan produced a significantly higher number 
of responders than losartan (62% versus [vs] 55%; P=0.02) 
at the 8-week treatment endpoint. Valsartan 80/160 mg 
monotherapies were shown to be effective and well-tolerated 
in management of mild to moderate essential hypertension. 
However, valsartan 160 mg had a significantly higher 
responder rate than 100 mg losartan.15
Renal protection
In addition to strict glycemic and blood pressure control, 
numerous studies have confirmed the role of renal protec-
tion by RAAS blockade. Studies in diabetic animals sug-
gested that intraglomerular hypertension and glomerular 
hypertrophy play an important role in diabetic nephropathy. 
Therefore, reducing the intraglomerular pressure by RAAS 
blockade should minimize the progression of or even prevent 
glomerular disease in the absence of glycemic control.
Experimental studies suggest that the nondihydropyridine 
CCBs can also retard the progression of diabetic nephropa-
thy. However, diltiazem alone was associated with increased 
tubulo-interstitial fibrosis and global glomerulosclerosis, but 
this effect can be prevented by combination therapy with 
RAAS blockers.
In the Reduction of Endpoints in Non-Insulin-Dependent 
Diabetes with the Angiotensin II Antagonist Losartan 
(RENAAL) trial, 1,513 patients with diabetic nephropa-
thy were randomly assigned to receive either losartan or 
placebo in addition to conventional antihypertensive therapy. 
Losartan retarded the progression to end-stage renal failure 
by 28% and reduced the doubling of the plasma creatinine by 
25% after a mean follow-up of 3.4 years. These benefits were 
again not associated with the differences in blood pressure 
levels between two treatment groups.16
Treatment of heart failure resulting  
from systolic dysfunction
Blockade of the RAAS system is a key component of treat-
ment for systolic heart failure, as it improves morbidity and 
mortality in these patients. ARBs act through a different 
mechanism than ACE inhibitors, although both reduce the 
stimulation of angiotensin II receptors.
A meta-analysis including 1,896 patients was performed 
on the basis of six controlled, double-blind, multiple-dose 
studies, regardless of sample size or duration of follow-up. 
There were 36 deaths in the losartan groups compared with 
47 in the control groups (3.12% vs 6.35%; P=0.004) during 
the double-blind periods. In this analysis, treatment with 
losartan provided a beneficial effect on survival. However, 
because the number of deaths in these studies was relatively 
small and the follow-up was relatively short, the mortality 
benefit of losartan remained controversial.17
In the Heart Failure Endpoint Evaluation of  Angiotensin II 
Antagonists Losartan trial (HEAAL), slightly but significantly 
better outcomes were obtained with higher doses of losartan 
in 3,846 patients intolerant to ACE inhibitors. At a median 
follow-up of 4.7 years, patients receiving losartan 150 mg 
had a significantly lower incidence of cardiovascular death 
(43% vs 46%) or hospitalization for heart failure (23% vs 
26%) than those receiving losartan 50 mg. Renal dysfunc-
tion, hypotension, and hyperkalemia were more common in 
the 150 mg than in the 50 mg group, but the discontinuation 
rates were similar in both groups.18
In the 2012 Cochrane review, ARBs had a borderline 
statistically significant effect on total mortality compared 
with placebo, with a relative risk of 0.87. In addition, drug 
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withdrawals resulting from adverse effects were significantly 
less common with ARBs when compared with ACE inhibi-
tors, with a relative risk of 0.63.19
The American College of Cardiology/American Heart 
Association and European Society of Cardiology therefore 
supported the use of ARBs in patients with current or prior 
symptoms of heart failure resulting from systolic dysfunction, 
especially in those who are intolerant of ACE inhibitors.20,21
Treatment of heart failure resulting  
from diastolic dysfunction
Regression of left ventricular hypertrophy is an important 
therapeutic target for patients with hypertension because it 
may improve diastolic function. A meta-analysis published 
in 2003 showed that angiotensin II receptor blockers were 
the most effective drug class for the regression of left ven-
tricular hypertrophy, followed by calcium channel blockers 
and ACE inhibitors.22
Losartan has been extensively evaluated for its benefit 
in heart failure resulting from diastolic dysfunction. After 
1 year of losartan-based regimen for hypertension, param-
eters of diastolic function as measured by echocardiogram 
improved in patients with reductions in left ventricular 
mass.23 This finding was supported by another study, which 
evaluated the myocardial stiffness quantified by transvenous 
endomyocardial biopsy. After 1-year treatment with losar-
tan, collagen volume fraction and left ventricular stiffness 
significantly decreased in patients with severe myocardial 
fibrosis. Therefore, losartan has the ability to induce regres-
sion of severe myocardial fibrosis, resulting in diminution of 
myocardial stiffness in hypertensive patients.24
The clinical benefit of losartan was demonstrated by a 
large randomized controlled trial aiming to compare the 
efficacy of a losartan-based regimen with that of an atenolol-
based regimen. Losartan was shown to prevent more car-
diovascular morbidity and death than atenolol for a similar 
reduction in blood pressure, and it was better tolerated.25 In 
addition, improved quality of life in patients with heart failure 
resulting from diastolic dysfunction was also demonstrated 
in small, randomized control trials.26,27
Urate-lowering effect of losartan
Among patients with hypertension, the concurrent use of 
losartan can reduce plasma urate levels; the use of other ARBs 
or ACE inhibitors does not. In a small prospective study 
comparing the urate-lowering effect of losartan and irbesartan, 
4 weeks of losartan decreased serum uric acid levels by 9%, 
whereas irbesartan had no effect.28 In an in vitro study, 
losartan, but not other ARBs, inhibited the renal urate anion 
exchanger that partially mediates urate reabsorption.29
In a randomized controlled trial comparing the efficacy of 
enalapril and losartan in patients with hypertension, losartan, 
but not enalapril, reduced plasma urate levels; there was no 
significant difference in other metabolic parameters between 
the two groups.30
The urate-lowering effect of losartan was also demonstrated 
in patients receiving diuretics. One thousand one hundred and 
sixty-one patients with mild to moderate hypertension were 
randomly assigned to receive losartan, losartan plus hydrochlo-
rothiazide, or candesartan for 12 weeks. The serum urate levels 
decreased, remained the same, or increased in those given losar-
tan, losartan plus hydrochlorothiazide, and candesartan, respec-
tively.31 Although uric acid excretion is initially increased, there 
appears to be little risk for uric acid nephropathy with losartan 
because of the concurrent elevation in urine pH resulting from 
reduced bicarbonate reabsorption.32 As a result, there was little 
or no increase in the urinary excretion of insoluble uric acid.
Safety and tolerability of losartan
The incidence of cough is lower in patients treated with 
ARBs. Although there was no direct comparison between 
losartan and other ACE inhibitors, the magnitude of this 
difference was demonstrated in a meta-analysis that directly 
compared the rate of cough in ARBs and ACE inhibitors.33 
The rates of cough were 3.2% and 9.9%, respectively, 
although there was significant statistical heterogeneity among 
the studies included in the meta-analysis.
The risk for angioedema appears to be lower with ARBs 
than ACE inhibitors. However, angioedema had been 
reported with losartan.34 The pathogenesis of angioedema 
with ARBs is unclear, but an increase in tissue bradykinin 
levels or nonkinin factors may be involved.
Hypotension appears to be more common with ARBs 
than ACE inhibitors. However, most of the patients who 
developed hypotension were taking multiple antihyperten-
sive drugs and had other comorbidities. Therefore, there was 
no conclusive evidence to support the idea that the risk for 
hypotension is more common with ARBs.
Clinical efficacy of losartan  
in Asian populations
Blood pressure control
Although there was no direct comparison of losartan with 
other ARBs for the treatment of hypertension in an Asian 
population, a multicenter study recruiting more than 200 
Asian patients in the People’s Republic of China, South 
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Korea, Taiwan, and Peru showed that losartan 50 mg plus 
hydrochlorothiazide 12.5 mg was superior to valsartan 80 mg 
in the treatment of hypertension.
Patients with suboptimal control of blood pressure with 
valsartan 80 mg were switched to a losartan plus hydrochloro-
thiazide combination. The mean reductions after switching were 
8.1 and 8.3 mmHg for systolic and diastolic blood pressure, 
respectively. The goal of diastolic blood pressure was achieved 
in 72 of the patients with hypertension previously not controlled 
by valsartan 80 mg. Combination therapy was generally well-
tolerated, with a mean compliance rate of more than 99%.35
Otherwise, most of the studies on the efficacy and safety 
of losartan were conducted in the Japanese cohorts. They 
demonstrated similar clinical efficacy of losartan, as men-
tioned earlier.
Another, similar, study was published in 2009, comparing 
the efficacy of the losartan plus hydrochlorothiazide combina-
tion with other ACE inhibitors and ARBs. In this 12-week, 
open-label trial, patients with suboptimal control of blood pres-
sure despite the use of ACE inhibitors or ARB monotherapy 
were switched to losartan 50 mg plus hydrochlorothiazide 
12.5 mg. At 4 and 8 weeks, patients who did not achieve target 
blood pressure were given losartan 100 mg plus hydrochloro-
thiazide 12.5 mg and losartan 100 mg plus hydrochlorothiazide 
25 mg, respectively. After 8 weeks, 73.5% of the patients 
reached their blood pressure goal; 78.1% of the patients 
reached their blood pressure goal at 12 weeks. The mean 
reductions from baseline systolic and diastolic blood pressure 
at 8 weeks were 16.7 and 12.1 mmHg, respectively.
This study suggested that switching Asian patients with 
suboptimal blood control with ACE inhibitors or ARBs to 
a losartan plus hydrochlorothiazide combination was more 
effective without compromising tolerability.
Renal protection
A study conducted in Singapore compared the renal protec-
tive efficacy of losartan with quinapril. Forty-one ARB- and 
ACE inhibitor–naïve participants with type 2 diabetes and 
albuminuria were given either 50 mg losartan or 20 mg qui-
napril for 4 weeks, with a 4-week wash-out period between 
interventions in a crossover fashion.
The use of losartan showed a significant reduction 
in albuminuria, as measured by urine protein over crea-
tinine ratio, when compared with the use of quinapril 
(−93 mg/g vs −49 mg/g; P=0.025). The reduction in albuminu-
ria was not associated with the reduction in blood pressure 
levels, as the systolic and diastolic blood pressure reductions 
were similar between two treatment groups. However, because 
of the short study duration, the long-term efficacy of losartan 
in renal protection should be further evaluated.36
The RENAAL study was a double-blind, randomized, 
placebo-controlled trial comparing the renal protective effects 
of losartan on a background of conventional antihypertensive 
therapies in more than 1,500 patients with type 2 diabetes and 
nephropathy. In this multiethnic trial, 252 Asian participants 
were recruited, most of whom were from Japan, Hong Kong, 
Malaysia, and Singapore.37
Although there was no significant difference in blood 
pressure reduction and the composite endpoints of cardiovas-
cular mortality and morbidity between two groups, losartan 
reduced the risk of doubling of serum creatinine, end-stage 
renal disease, or all-cause mortality in Asian patients by 
35% (P=0.02). The use of losartan also reduced the level of 
proteinuria by 47% (P,0.001) and the rate of decrease in 
renal function by 31% (P=0.007).37
Another study had evaluated the efficacy of losartan plus 
conventional antihypertensive therapies in the cost reduction 
associated with end-stage renal disease. The use of losartan 
reduced the number of days with end-stage renal failure 
by 37.9 per patient over the course of 3.5 years compared 
with conventional antihypertensive therapies. This reduc-
tion resulted in a decrease in the cost ranging from $910 to 
$4,346 per patient over the six regions. After calculation of 
the cost of losartan, the net savings in each of the six regions 
ranged from $55 to $515 per patient.38
The effects of losartan plus hydrochlorothiazide were 
compared with losartan alone in Japanese diabetic patients 
with hypertension. Thirty Japanese diabetic patients with 
hypertension were randomly assigned to receive losartan 
alone for the first 3 months and then combination therapy for 
the next 3 months, or vice versa. The decreases in systolic and 
diastolic blood pressure during combination treatment were 
significantly greater than in treatment with losartan alone. 
However, both treatment groups had significant and similar 
decrease in urinary albumin excretion, although there was no 
significant difference in metabolic change during the mono- 
and combination therapies.39 This study also confirmed that 
the efficacy of losartan in renal protection is independent of 
the reductions in blood pressure levels.
Treatment of heart failure resulting  
from diastolic dysfunction
Losartan was compared with amlodipine in a prospective, 
randomized study to assess the effects on left ventricular 
diastolic function and atherosclerosis of the carotid artery 
in patients with mild to moderate hypertension. A total 
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of 57 patients were randomly assigned to losartan- or 
amlodipine-based treatment groups and were followed-up 
for 18 months. Blood pressure was similarly reduced by 
both regimens. Although losartan shortened the transmitral 
E-wave deceleration time and amlodipine reduced left ven-
tricular mass index, there was no significant difference in 
these parameters between the two groups. However, the mean 
carotid intima-media thickness as well as plaque score signifi-
cantly increased in the amlodipine-based treatment groups, 
but not in the losartan-based treatment groups. Therefore, 
under similar reduction of blood pressure, losartan is likely 
effective in protecting the progression of atherosclerosis of 
the carotid artery compared with amlodipine, but the exact 
mechanism of this observation has not been fully explained 
by this study.40
Urate-lowering effect of losartan
A multicenter, randomized, double-blind controlled trial was 
conducted in the People’s Republic of China to compare the 
urate-lowering effects of losartan and irbesartan in Chinese 
patients with mild to moderate essential hypertension. In this 
study, 162 Chinese patients were randomly assigned to the 
losartan group, and 163 patients were randomly assigned to 
the irbesartan group.
This study showed that losartan 50 mg once daily pro-
duced a significant decrease in serum urate levels from 
422 mmol/L at baseline to 367 mmol/L at week 4 (P=0.0001). 
The use of losartan 50 or 100 mg once daily for 8 weeks 
further decreased the serum urate levels to 359 mmol/L. 
However, there was no significant change in serum urate 
levels in the irbesartan group throughout the study.41
Safety and tolerability of losartan  
in Asian populations
Data from the RENAAL study showed that Asian patients had 
the lowest rates of discontinuation. In Asian patients, losartan 
was well-tolerated with no increase in incidence of cough.37 
In India, losartan was proven to be effective and safe. Data 
were obtained in 347 patients from 140 general physicians. 
The study revealed that losartan potassium was used in the 
treatment of mild to moderate hypertension with excellent 
to good response in 98.8% of the cases. Mild adverse reac-
tions were reported in 5.8% of the cases. None of the adverse 
reactions were severe enough to require discontinuation of 
therapy or to need hospitalization.42
Another study from Japan evaluated the long-term 
safety of losartan plus hydrochlorothiazide combinations. 
After 1 year of treatment, only 11% of the patients developed 
clinical and laboratory adverse events, but serious abnormali-
ties were not observed.43
Conclusion
The health burden of hypertension in Asia is increasing as a 
result of changes in lifestyle, increased incidence of obesity, 
and improved life expectancy. To optimize the control of 
hypertension, appropriate use of antihypertensive medica-
tions is crucial. New National Institute for Clinical Excel-
lence guidelines suggested the use of ACE inhibitors or ARBs 
as the first-line treatment for essential hypertension. However, 
a higher incidence of dry cough with ACE inhibitors was 
reported in Asian populations. Therefore, ARB may be more 
suitable for Asian patients with hypertension.
The efficacy and safety have been evaluated in several 
studies, mainly in Japanese cohorts. Losartan or a losartan 
plus hydrochlorothiazide combination are effective in Asian 
patients with essential hypertension. In addition, other ben-
efits of losartan in terms of renal protection in patients with 
diabetes and treatment of heart failure resulting from diastolic 
dysfunction were also demonstrated in Asian populations. 
More important, this drug was proven to be safe and well-
tolerated in Asian patients.
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